Tag: blood-brain barrier

A phase II clinical trial led by scientists at the Georgetown University Medical Center that tests the efficacy of the drug nilotinib approved for leukemia, in the treatment of Parkinson’s Disease suggests that the drug targets vascular and autophagy defects in the progression of Parkinson’s Disease. Nilotinib, 300 mg, reverses these effects via altering miRNA expression, suggesting epigenomic changes that may underlie long-term disease-modifying effects.